GAP President John Dwyer was quoted in Pink Sheet in regard to the Centers for Medicare and Medicaid Services’ proposed National Coverage Decision. The Centers for Medicare and Medicaid Services’ proposed eligibility criteria for the research sites capable of conducting clinical trials for monoclonal antibody drugs for Alzheimer’s disease could be met in just 28 […]
GAP President John Dwyer, on behalf of the organization, joined other Alzheimer’s advocates in Washington D.C. for the ‘Rally for Access’ on March 15, 2022. The ‘Rally for Access’ gathered these organizations to remind the public what is at stake if the Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) is accepted. […]
A new seven-figure ad campaign takes aim – again – at Medicare’s pending coverage decision on Alzheimer’s disease anti-amyloid drugs. UsAgainstAlzheimer’s launched the $1 million-plus national effort Sunday, including a TV ad that ran across the the day’s morning talk news shows. The group is the latest to push back on the Centers for Medicare […]
GAP-Net Site Charter Research’s Jeff Pohlig, CEO, wrote an Op-Ed about how volunteering can improve your health and your community. Unfortunately, over 90% of research studies are delayed because of slow recruitment. These delays may be affecting the treatment of your neighbor, loved one, co-worker or friend. Floridians facing Alzheimer’s need clinical trial volunteers to […]
GAP President John Dwyer was featured in Pink Sheet talking about the cost of Aduhelm affecting the Centers for Medicare and Medicaid Services NCD. US Medicare coverage policy is supposed to be fenced off from considerations about the cost of a prescription drug (or other item or service). But the notion that the cost of […]
Being Patient answers some common questions regarding the Centers for Medicare and Medicaid Services (CMS) proposal, and GAP President John Dwyer mentions how this could affect future Alzheimer’s trials and treatments. The CMS proposed a plan that could strip Alzheimer’s drug Aduhelm of public Medicare coverage. The result was widespread confusion. We clarify some aspects […]
GAP President John Dwyer was quoted in NJ.com about the future of Alzheimer’s treatments if the CMS National Coverage Decision (NCD) proposal is approved. Every day in this country, an estimated 1,000 people progress from moderate Alzheimer’s dementia to the final and most severe stage of the disease. That’s a grim statistic in its own […]
GAP President John Dwyer was quoted in Politico talking about the difficulty of having a diverse population pool in Alzheimer’s clinical trial, and how unlike that is to achieve if the CMS proposal is approved. Drugmakers and patient advocacy groups are waging a campaign to cast Medicare officials as villains after the program limited coverage […]
Watch GAP President John Dwyer and GAP’s Senior Advisor, Dr. Lynne Hughes, talk about our Ixico partnership and our Bio-Hermes study.
New GAP-Net site El Faro Health and Therapeutics has opened in Rio Grande City, TX. The below article was translated from Spanish to English. The original, Spanish version is linked at the bottom. A new clinical research center to study Alzheimer’s and its impact among Hispanics, the group with the highest prevalence of this disease […]
Alzheimer’s World Directs Eyes on the Rio Grande Valley as Acclaimed Family Physician Opens New Facility in Rio Grande City with Highest Alzheimer’s Rate in the Country The Global Alzheimer’s Platform Foundation® (GAP) and Dr. Antonio Falcon celebrated the opening of El Faro Health & Therapeutics in Rio Grande City, TX on Saturday, marking a […]
GAP-Net Site, El Faro Health and Therapeutics, was opened in Starr County, Texas led by Drs. Antonio and James Falcon. El Faro Health & Therapeutics will be the first private clinical research site in Starr County, TX. This groundbreaking initiative will bring critical Alzheimer’s-related research and care to a community that has been historically underrepresented […]
GAP is proud to support the grand opening of #GAPNet El Faro Health and Therapeutics, the first private research site in Starr County, Texas. Starr County is a 97% Hispanic Community with the highest prevalence of Alzheimer’s disease in America. Legendary Starr County physician and Baylor College of Medicine Trustee, Dr. Antonio ‘Tony’ Falcon is […]
GAP President John Dwyer commends President Joe Biden on his commitment to fight Alzheimer’s, as well as calls on Congress to pass ARPA-H. Normally, presidential proclamations aren’t news. However, as the United States sinks deeper into a worsening Alzheimer’s public health crisis, President Joe Biden is making his priorities on the disease abundantly clear. Prior […]
Microsoft and Gates Ventures founder, Bill Gates, mentions GAP’s Bio-Hermes study to the World Dementia Council. We’ve all heard the statistics: Today, nearly 55 million people suffer from Alzheimer’s disease or related dementias. According to the WHO, dementia is the fastest growing burden on healthcare systems and the seventh leading cause of death worldwide. Its […]
Three GAP-Net Sites, The Cognitive and Research Center of New Jersey, Princeton Medical Institute, and Advanced Memory Research Institute of New Jersey are hosting a state wide FREE memory screening for individuals 50+. If you’re worried about the threat of dementia, there’s something you can do right now to reduce your risk. Get your memory […]
GAP-Net Site, Axiom Clinical Research of Florida, talks about the Bio-Hermes study and what people from traditionally underserved communities can do to get involved in research. We need an accessible means of diagnosing Alzheimer’s disease and research that demonstrates that new therapies and diagnostic tools work for all people. As a neurological researcher and an […]
GAP’s Bio-Hermes study was featured in BlackNews.com about our groundbreaking commitment to diversity. Washington, DC — Research sites in Florida, Illinois, Kansas, Texas, and New York are now recruiting participants for The Global Alzheimer’s Platform Foundation® (GAP)’s Bio-Hermes Study – a breakthrough Alzheimer’s clinical trial searching for cost-effective methods to assess the signs of the disease. It is […]
GAP-Net site, the University of Southern California, received over 90 grants totaling $92 million in 2020. USC’s bench is deep and its scope is wide when it comes to research on Alzheimer’s disease. In Paul Thompson’s lab, researchers query a vast trove of brain images and DNA from all over the world to glean insights that would be […]
GAP’s Tamiko MaGee-Rodgers, Associate Director for Recruitment and Strategic Initiatives, wrote an article in the Orlando Times about the Black community getting involved in Alzheimer’s disease clinical trials and the Bio-Hermes study at GAP-Net site, Charter Research. At the Global Alzheimer’s Platform Foundation (GAP), our focus is speeding the delivery of innovative therapies to people […]
GAP-Net site, Progressive Medical Research, was featured in the Daytona Times for the Bio-Hermes study and how to get a free brain scan. The effects of Alzheimer’s disease on Black families across the U.S. are devastating. If nothing is done to mitigate these effects, according to researchers at Florida International University and UsAgainstAlzheimer’s, by 2030 […]
GAP President John Dwyer and GAP-Net site, Charter Research, were featured in Being Patient talking about the Bio-Hermes study, our commitment to diversity, and the tests used in the study. Scientists have made strides in improving the precision of diagnosing Alzheimer’s, but available diagnostic tools that measure Alzheimer’s biomarkers remain inaccessible for many patients. So, […]
GAP President John Dwyer and GAP-Net site, Axiom Clinical Research, were featured in the Florida Courier about the Bio-Hermes study and the importance of Black and African American participation in Alzheimer’s trials. The effects of Alzheimer’s Disease on the Black families across the U.S. are devastating. If nothing is done to mitigate these effects, according […]
GAP-Net site Washington Univeristy in St. Louis’ Dr. Joy Snider about the pros and cons about the approval of Aduhelm (Aducanumab). The recent FDA approval of a new Alzheimer’s drug has some researchers concerned — aside from its $56,000-a-year price tag. It’s the first Alzheimer’s drug to be approved since 2003. It’s called aducanumab and is marketed […]